Structure of compound 9

trimethyl-lock prodrug of HCV NS5A inh.

improved bioavailability in preclinical species

from derivatization of pibrentasvir

J. Med. Chem., Sep. 3, 2020

AbbVie, North Chicago, IL

“compound 9” is an investigational prodrug of pibrentasvir (ABT-530), a key component of AbbVie’s marketed HCV combination Mavyret. Pibrentasvir (PIB) is the largest approved oral small molecule since 1983 (MW…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.